Search - tctmd.com

Displaying 1 - 20 of 125

Sort: Relevancy | Date

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

Presentation TCT 2025

TCT 66: Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction: the DAPA-STEMI Trial

Presenter: Claudio Laudani

October 28, 2025

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

October 07, 2025

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

What’s Going to Be Hot at ESC Congress 2025?

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

News Daily News

Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension

July 14, 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

News Conference News ESC Heart Failure 2025

No Additional Gain in Quality of Life With Dapagliflozin on Top of TAVI

May 20, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

January 31, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

Presentation TCT 2024

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

Presenter: Bu-Yuan Hsiao

October 29, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.